Table 2.

Univariate Cox Regression Analysis of Disease-free and Overall Survival in Relation to Clinicopathologic Features in the Treated Group

Characteristics	Number of patients	Disease -free survival		Overall survival
		HR (95% CI)	P value	HR (95% CI)	P value
Gender			0.81		0.82
Females (ref)	88	1.00		1.00
Males	124	0.96 (0.69–1.33)		0.96 (0.68–1.35)
Age (yrs)			0.04		0.60
<60 (ref)	88	1.00		1.00
60–70	77	0.81 (0.57–1.15)		1.28 (0.80–2.05)
>70	47	0.55 (0.35–0.87)		1.20 (0.74– 1.95)
Blood loss	212	1.00 (1.00–1.00)	0.21	1.00 (1.00–1.00)	0.10
Neoadjuvant therapy			0.09		0.59
Group 1	39	1.00		1.00
Group 2	66	0.66 (0.23–1.88)	0.43	0.75 (0.26–2.15)	0.59
Group 3	70	0.53 (0.19–1.49)	0.23	0.55 (0.20–1.54)	0.25
Group 4	32	0.84 (0.30–2.32)	0.74	0.71 (0.26–1.98)	0.52
Group 5	5	1.00 (0.35–2.89)	1.00	0.74 (0.25–2.17)	0.58
Tumor size			0.15		0.24
≤2cm (ref)	79	1.00		1.00
>2cm	133	1.28 (0.92–1.80)		1.24 (0.87–1.76)
Margin			0.100		0.008
Negative (ref)	188	1.00		1.00
Positive	24	1.48 (0.93–2.34)		1.88 (1.18–3.00)
Tumor differentiation			0.21		0.15
Well-moderate (ref)	134	1.00		1.00
Poor	78	1.24 (0.89–1.72)		1.29 (0.92–1.81)
Pathologic tumor stage			0.08		0.02
ypT1–ypT2 (ref)	13	1.00		1.00
ypT3	199	1.97 (0.92–4.22)		3.38 (1.25–9.15)
Lymph nodes			0.007		0.002
Negative (ref)	87	1.00		1.00
Positive	125	1.58 (1.13–2.20)		1.77 (1.24–2.53)
AJCC Stage			0.01		0.003
Stage IA and IB (ref)	10	1.00		1.00
Stage IIA	77	1.94 (0.77–4.87)		4.57 (1.11–18.88)
Stage IIB	125	2.82 (1.14–6.95)		6.99 (1.72–28.45)
Perineural invasion			0.002		<0.001
Absent (ref)	89	1.00		1.00
Present	123	1.69 (1.21–2.36)		1.95 (1.36–2.78)

Abbreviations: HR, hazard ratio; CI, confidence interval; ref, reference